Literature DB >> 22294392

Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents.

Denise C Connolly1, Harvey H Hensley.   

Abstract

Epithelial ovarian cancer (EOC) is the most commonly fatal gynecologic malignancy in developed countries. Most EOC patients are diagnosed at an advanced stage when disease has spread beyond the ovary. While many patients initially respond to surgery and chemotherapy, the long-term prognosis is generally unfavorable, with recurrence and development of drug-resistant disease. There is a critical need to identify new therapeutic agents that prolong disease-free intervals and effectively manage recurrent disease. Murine models of ovarian carcinoma are excellent models to study tumor biology in the search for new treatments for EOC. Described in this unit are methods for establishing xenograft or allograft models of EOC using ovarian carcinoma cell lines, in vivo imaging strategies for detection and quantification of EOC in transgenic and in xenograft/allograft models, and procedures for necropsy and pathological evaluation of experimental animals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 22294392     DOI: 10.1002/0471141755.ph1412s45

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  8 in total

1.  Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice.

Authors:  Harvey H Hensley; Navid A Roder; Shane W O'Brien; Laura E Bickel; Fang Xiao; Sam Litwin; Denise C Connolly
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

2.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

Review 3.  VSV based virotherapy in ovarian cancer: the past, the present and …future?

Authors:  Beata Urszula Orzechowska; Marcin Jędryka; Katarzyna Zwolińska; Rafał Matkowski
Journal:  J Cancer       Date:  2017-07-22       Impact factor: 4.207

4.  Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.

Authors:  G Semenova; D S Stepanova; C Dubyk; E Handorf; S M Deyev; A J Lazar; J Chernoff
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 5.  Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches.

Authors:  Razia Zakarya; Viive M Howell; Emily K Colvin
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

6.  Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.

Authors:  Bridget A Quinn; Tiffany Brake; Xiang Hua; Kimberly Baxter-Jones; Samuel Litwin; Lora Hedrick Ellenson; Denise C Connolly
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

7.  Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.

Authors:  Thuy-Vy Do; Jeff Hirst; Stephen Hyter; Katherine F Roby; Andrew K Godwin
Journal:  Oncotarget       Date:  2017-07-05

8.  The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.

Authors:  Shiho Fukui; Kazunori Nagasaka; Yuko Miyagawa; Ryoko Kikuchi-Koike; Yoshiko Kawata; Ranka Kanda; Takayuki Ichinose; Takeru Sugihara; Haruko Hiraike; Osamu Wada-Hiraike; Yuko Sasajima; Takuya Ayabe
Journal:  Oncotarget       Date:  2019-10-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.